The Board of Directors of Nordic Nanovector ASA (the "Company") has resolved to grant 340,000 options to Lisa Rojkjaer, MD to subscribe for shares in the Company. Dr. Lisa Rojkjaer has been employed as the Company's new CMO.
Each option, when exercised, will give the right to acquire one share in the Company. The options are granted without consideration. Pursuant to the vesting schedule, 25% of the options will vest 12 months after the day of grant (as long as the option holder is still employed). Thereafter, 1/36 of the remaining options will vest each month as long as the option holder is still employed, with the first 1/36 vesting 13 months after the day of grant. The exercise price of the options is NOK 66.74. The exercise price is equal to the volume weighted average trading price of the shares of the Company on Oslo Børs the last five trading days prior to the date of the grant. Options that have not been exercised will lapse 7 years after the date of grant.
Dr. Rojkjaer does currently not hold any shares in the Company.
About Nordic Nanovector:
Nordic Nanovector is a biotech company
focusing on the development and commercialisation of novel targeted
therapeutics in haematology and oncology. The Company's lead
clinical-stage product opportunity is Betalutin®, the first in a new
class of Antibody-Radionclide-Conjugates (ARC) designed to improve upon
and complement current options for the treatment of non-Hodgkin Lymphoma
(NHL). NHL is an indication with substantial unmet medical need and
orphan drug opportunities, representing a growing market worth over USD
12 billion by 2018. Betalutin® comprises a tumour-seeking anti-CD37
antibody (HH1) conjugated to a low intensity radionclide (lutetium-177).
The preliminary data has shown promising efficacy and safety profile in
an ongoing Phase1/2 study in a difficult-to-treat NHL patient
population. The Company is aiming at developing Betalutin® for the
treatment of major types of NHL with first regulator submission
anticipated in 1H 2019. Nordic Nanovector intends to retain marketing
rights and to actively participate in the commercialisation of
Betalutin® in core markets, while exploring potential distribution
agreements in selected geographies. The Company is committed to
developing its ARC pipeline to treat multiple selected cancer
indications. Further information about the Company can be found at www.nordicnanovector.com.
This information is subject to duty of disclosure pursuant to Section
4-2 and 5-12 of the Norwegian Securities Trading Act.
This information was brought to you by Cision http://news.cision.com
View source version on businesswire.com: http://www.businesswire.com/news/home/20161114006728/en/
Contacts:
Tone Kvåle, +47 91 51 95 76
Chief Financial
Officer
tkvale@nordicnanovector.com